In this first of two videos on the refractory thyroid cancer, Marcia Brose, MD, discusses the approved multikinase inhibitors sorafenib and lenvatinib for progressive, RAI-refractory differentiated thyroid cancer. Dr. Brose played a key role in the approval of sorafenib for thyroid cancer in 2013, and is widely considered a leading expert in the treatment of refractory thyroid cancer.
View the 2016 update on this topic here